XML 70 R55.htm IDEA: XBRL DOCUMENT v3.20.4
License Agreements - Syros (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 12 Months Ended
Jan. 31, 2018
USD ($)
item
$ / shares
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Feb. 28, 2018
USD ($)
Jan. 08, 2018
$ / shares
License agreements            
Long term investments   $ 222,301 $ 133,657      
Research and development expense   2,215,942 1,154,111 $ 1,197,957    
Unrealized gain (loss) on long term investments   10,426 34,458 (44,093)    
Syros Pharmaceuticals, Inc.            
License agreements            
Number of program targets | item 7          
Upfront payment under license agreement $ 10,000          
Fair value of shares on the issuance date   $ 10,200 6,500      
Ownership percentage (as a percent)   2.00%        
Unrealized gain (loss) on long term investments   $ 3,700 $ 1,300 $ (3,700)    
Syros Pharmaceuticals, Inc. | Stock purchase agreement            
License agreements            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.8          
Purchase price of common stock $ 10,000          
Per share price | $ / shares $ 12.61         $ 9.77
Lock-up period 12 months          
Discount for lack of marketability $ 100          
Fair value of shares on the issuance date 7,600          
Long term investments 7,600          
Research and development expense $ 2,400          
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement            
License agreements            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.1          
Purchase price of common stock $ 1,400          
Per share price | $ / shares $ 9.55          
Long term investments         $ 1,400  
Syros Pharmaceuticals, Inc. | Maximum            
License agreements            
Target selection and option exercise fee payment $ 54,000          
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement 50,000          
Syros Pharmaceuticals, Inc. | Sales and Commercial Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement $ 65,000